Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shed light on. While Cramer still backed the company, he did express uncertainty about its future as he stated: “What I’m thinking ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for long-term investors to capitalize now.

Eli Lilly closed at $1.87, ranked 34th in trading volume on July 22, 2025. BMO Capital remains bullish, reiterating a buy ...

Nvidia is not just surfing the AI wave; it's engineering the tsunami with a projected market cap of $7 trillion by 2028. With ...

FDLO's sector-neutral approach and selective stock picking drive strong profitability and historical earnings growth. Read why FDLO ETF is a Buy.

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and ...